Risk of cutaneous adverse reactions associated with allopurinol or febuxostat in real‐world patients: A nationwide study

Abstract

Febuxostat can be considered an alternative for patients carrying risk factors for allopurinol-related CARs. However, since there were fatal cases of febuxostat-related CARs, the closely monitoring of symptoms of CARs during the initiation of febuxostat is still warranted.